Drug Repurposing: Finding New Therapeutic Uses for Existing Pharmaceuticals

Dr. Rahul Nair*
Head of the Department
King Edward Memorial (KEM) Hospital,
Mumbai

Abstract: *This paper explores the concept of drug repurposing as a viable strategy for discovering new therapeutic uses for existing pharmaceuticals. It examines various approaches to drug repurposing, including serendipitous discoveries, target-based screening, pathway analysis, computational methods, drug combination therapy, and clinical data mining. The paper discusses the advantages of drug repurposing over traditional drug development and highlights successful examples of repurposed drugs. It also addresses challenges and future directions in the field of drug repurposing.*
Keywords: Drug Repurposing, Therapeutic, Pharmaceuticals etc

Introduction

The landscape of pharmaceutical research and development is continually evolving, with the quest for novel therapeutics driving innovation and investment. However, traditional drug discovery and development processes are often protracted, costly, and fraught with challenges, leading to high attrition rates and significant time-to-market delays. In this context, drug repurposing has emerged as a promising strategy to expedite the identification and development of new therapies by leveraging existing pharmaceutical compounds for alternative indications. Drug repurposing, also known as drug repositioning or drug reprofiling, involves the exploration of existing drugs that are already approved or undergoing clinical trials for one indication, with the aim of identifying new therapeutic uses in unrelated diseases or conditions. Unlike de novo drug discovery, which typically involves extensive preclinical and clinical development phases, drug repurposing offers several distinct advantages, including reduced development costs, shorter timelines, and a higher likelihood of success in clinical trials.

Approaches to Drug Repurposing

Drug repurposing encompasses a variety of approaches aimed at identifying new therapeutic uses for existing drugs. These approaches leverage existing knowledge about drug safety, pharmacokinetics, and mechanisms of action to expedite the discovery and development of treatments for different diseases. Some of the key approaches to drug repurposing include:

- **Serendipitous Discoveries**: Historically, many instances of drug repurposing have occurred serendipitously, where a drug being used for one condition is found to be effective for treating another condition. These discoveries often arise from anecdotal observations, clinical experience, or unexpected outcomes in clinical trials. Examples include the repurposing of sildenafil (Viagra) from a cardiovascular drug to a treatment for erectile dysfunction and the repurposing of thalidomide from a sedative to a therapy for multiple myeloma.

- **Target-Based Screening**: This approach involves screening libraries of existing drugs against specific molecular targets or pathways implicated in a different disease. By identifying drugs that interact with the target of interest, researchers can identify potential candidates for repurposing. For example, drugs developed for cancer treatment may also target pathways involved in neurodegenerative diseases, leading to their repurposing for conditions like Alzheimer's or Parkinson's disease.

- **Pathway Analysis**: Drugs can be repurposed based on their known mechanisms of action and their ability to modulate shared biological pathways between diseases. By understanding the underlying pathways involved in different diseases, researchers can identify drugs that target similar pathways and may therefore be effective in treating multiple conditions. For example, drugs that target inflammation or immune responses may be repurposed for autoimmune diseases or inflammatory conditions.

- **Computational Approaches**: With the advent of bioinformatics and computational biology, researchers can now utilize algorithms and data mining techniques to analyze large datasets of drug and disease information. Computational approaches can help predict potential drug-disease associations based on similarities in molecular structure, biological activity, or clinical outcomes. By integrating diverse data sources, such as gene expression profiles, protein-protein interactions, and drug-target interactions, computational methods enable researchers to identify promising candidates for repurposing in a systematic and efficient manner.

- **Drug Combination Therapy**: Another strategy for drug repurposing involves combining existing drugs with different mechanisms of action to create synergistic effects or overcome resistance in certain diseases. This approach has been particularly successful in the treatment of cancer, where combination therapies can target multiple signaling pathways or overcome tumor heterogeneity. By repurposing existing drugs in novel combinations, researchers can enhance therapeutic efficacy while minimizing toxicity and side effects.

- **Clinical Data Mining**: Real-world data from electronic health records, clinical trial databases, and other sources can provide valuable insights into drug efficacy and safety in different patient populations. By analyzing large-scale datasets, researchers can identify

patterns and correlations that suggest potential new uses for existing drugs. Clinical data mining approaches can help prioritize candidates for repurposing based on clinical evidence and patient outcomes.

Advantages of Drug Repurposing

Drug repurposing offers several distinct advantages over traditional drug discovery and development approaches. These advantages contribute to its growing popularity as a strategy for identifying new therapeutic uses for existing drugs. Some of the key advantages of drug repurposing include:

- **Reduced Development Costs**: Drug repurposing typically requires fewer resources and less investment compared to de novo drug discovery and development. Since repurposed drugs have already undergone preclinical testing and safety assessments, much of the initial research and development work has already been completed. This can significantly reduce the time and cost required to bring a drug to market, making repurposing an attractive option for pharmaceutical companies and research organizations with limited resources.

- **Shorter Development Timelines**: The repurposing of existing drugs can lead to shorter development timelines compared to the development of new chemical entities. Since repurposed drugs have already been tested in humans for safety and pharmacokinetics, they can progress more rapidly through preclinical and clinical development phases. This accelerated timeline can help bring new treatments to patients more quickly, addressing unmet medical needs and improving patient outcomes.

- **Lower Risk of Failure**: Repurposed drugs have a lower risk of failure in clinical trials compared to new chemical entities. Since repurposed drugs have already demonstrated safety and tolerability profiles in humans, there is less uncertainty regarding their potential side effects and toxicities. Additionally, repurposed drugs often have well-characterized pharmacokinetic and pharmacodynamic properties, reducing the likelihood of unexpected drug interactions or adverse effects. This lower risk profile makes repurposed drugs attractive candidates for development, particularly in areas where the failure rate for new drugs is high.

- **Leveraging Existing Knowledge and Infrastructure**: Drug repurposing leverages existing knowledge about drug targets, mechanisms of action, and disease biology. Researchers can build upon the extensive literature and clinical experience surrounding existing drugs, facilitating the identification of new therapeutic uses. Additionally, repurposing utilizes existing infrastructure for drug manufacturing, distribution, and regulatory approval, further streamlining the development process. This allows for more efficient utilization of resources and accelerates the translation of research findings into clinical practice.

- **Potential for Drug Combinations**: Repurposed drugs can be combined with other drugs to create synergistic effects or enhance therapeutic outcomes. By leveraging the diverse mechanisms of action of existing drugs, researchers can develop combination therapies that target multiple disease pathways simultaneously. This approach has been particularly successful in the treatment of complex diseases such as cancer, where drug resistance and tumor heterogeneity pose significant challenges. By repurposing existing drugs in novel combinations, researchers can overcome these obstacles and improve treatment efficacy.

Successful Examples of Drug Repurposing

Drug repurposing has yielded numerous success stories, where existing drugs have been found to be effective in treating conditions beyond their originally approved indications. These examples highlight the potential of repurposed drugs to address unmet medical needs and improve patient outcomes. Some notable examples include:

- **Aspirin (Acetylsalicylic Acid):** Originally developed as a pain reliever and anti-inflammatory medication, aspirin has been repurposed for its cardiovascular protective effects. Clinical trials have demonstrated that low-dose aspirin therapy reduces the risk of heart attacks, strokes, and blood clots by inhibiting platelet aggregation and reducing inflammation. As a result, aspirin is now widely used for the prevention of cardiovascular events in patients with a history of heart disease or stroke.

- **Thalidomide**: Initially marketed as a sedative and antiemetic medication, thalidomide gained notoriety for its teratogenic effects during pregnancy. However, thalidomide has since been repurposed as a treatment for multiple myeloma, a type of blood cancer. Thalidomide and its derivatives, such as lenalidomide and pomalidomide, have demonstrated anti-cancer activity by inhibiting angiogenesis and modulating the immune system. These drugs are now integral components of treatment regimens for multiple myeloma and other hematologic malignancies.

- **Sildenafil (Viagra):** Originally developed as a medication for hypertension and angina, sildenafil was serendipitously found to induce penile erections in clinical trials. This unexpected side effect led to the repurposing of sildenafil as a treatment for erectile dysfunction. By inhibiting the enzyme phosphodiesterase-5 (PDE5), sildenafil enhances blood flow to the penis, resulting in improved erectile function. Viagra, the brand name for sildenafil, revolutionized the treatment of erectile dysfunction and remains one of the most widely prescribed medications worldwide.

- **Metformin:** Initially approved for the treatment of type 2 diabetes, metformin has attracted attention for its potential anti-cancer properties. Epidemiological studies have shown that diabetic patients treated with metformin have a lower incidence of certain cancers, suggesting a protective effect against tumorigenesis. Preclinical studies have further demonstrated that metformin inhibits tumor cell proliferation and enhances chemotherapy

sensitivity. Clinical trials are ongoing to investigate the repurposing of metformin for cancer prevention and treatment.

- **Propranolol:** Originally developed as a beta-blocker for the treatment of hypertension and angina, propranolol has been repurposed for the management of various non-cardiovascular conditions. In particular, propranolol has shown efficacy in the treatment of infantile haemangiomas, a common vascular tumor in children. By blocking beta-adrenergic receptors, propranolol induces vasoconstriction and reduces the proliferation of blood vessels, leading to regression of haemangiomas. Propranolol is now considered a first-line therapy for infantile haemangiomas and has transformed the management of this condition.

Conclusion

Drug repurposing represents a powerful strategy for identifying new therapeutic uses for existing pharmaceuticals, offering numerous advantages over traditional drug discovery and development approaches. Through serendipitous discoveries, target-based screening, pathway analysis, computational methods, drug combination therapy, and clinical data mining, researchers have successfully repurposed existing drugs to address unmet medical needs and improve patient outcomes. The advantages of drug repurposing, including reduced development costs, shorter timelines, lower risk of failure, leveraging existing knowledge and infrastructure, and the potential for drug combinations, highlight its potential to revolutionize the drug discovery and development paradigm. By capitalizing on existing drugs, researchers can expedite the translation of research findings into clinical practice, delivering safe, effective, and affordable therapies to patients in a more efficient and sustainable manner.

References

Aditya Ravi Agrelwar, Kevin Varkey Varghese, Rahul Kishore Peter, & Sameeksha Rajesh Jain. (2022). Website Development for Pharmaceuticals Equipments. *International Journal for Research Publication and Seminar*, *13*(3), 215–217. Retrieved from https://jrps.shodhsagar.com/index.php/j/article/view/560

Ankit, & Praveen Malik. (2016). PASS APPLICATION IN R&D OF NEW PHARMACEUTICALS. *International Journal for Research Publication and Seminar*, *7*(5), 11–14. Retrieved from https://jrps.shodhsagar.com/index.php/j/article/view/853

Avani Dave. (2021). Trusted Building Blocks for Resilient Embedded Systems Design. University of Maryland.

Dr Goutam Pradhan. (2024). A REVIEW OF THE RELATIONSHIPS BETWEEN PROGRESSION OF REFRACTIVE ERRORS & TRANSIENT DRUG INDUCED MYOPIA ALONG WITH TRANSIENT NEAR WORK INDUCED MYOPIA. *International Journal for Research Publication and Seminar*, *15*(1), 83–89. Retrieved from https://jrps.shodhsagar.com/index.php/j/article/view/334

Gallagher, E. J., & LeRoith, D. (2016). Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Annals of the New York Academy of Sciences, 1411(1), 31–50.

Hripcsak, G., Ryan, P. B., Duke, J. D., Shah, N. H., Park, R. W., & Huser, V. (2016). Characterizing treatment pathways at scale using the OHDSI network. Proceedings of the National Academy of Sciences, 113(27), 7329–7336.

Kanungo, S. (2024). Computer aided device for Managing, Monitoring, and Migrating Data Flows in the Cloud (Patent No. 6356178). GB Patent & Intellectual Property Office. https://www.registered-design.service.gov.uk/find/6356178

Kloner, R. A. (2017). Sildenafil therapy in cardiovascular disease. American Journal of Cardiovascular Drugs, 17(4), 287–298.

Léauté-Labrèze, C., Hoeger, P., Mazereeuw-Hautier, J., Guibaud, L., Baselga, E., Posiunas, G., ... & Ezzedine, K. (2015). A randomized, controlled trial of oral propranolol in infantile hemangioma. New England Journal of Medicine, 372(8), 735–746.

Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., ... & Smith, S. K. (2011). Impact of high-throughput screening in biomedical research. Nature Reviews Drug Discovery, 10(3), 188–195.

Menden, M. P., Iorio, F., Garnett, M., McDermott, U., Benes, C. H., Ballester, P. J., & Saez-Rodriguez, J. (2013). Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties. PLoS ONE, 8(4), e61318.

Ms. Pooja P. Raj, & Dr. Amrita Verma. (2023). Comparative study of face mask detection using CNN and SVM Algorithms. *International Journal for Research Publication and Seminar*, *14*(3), 61–66. Retrieved from https://jrps.shodhsagar.com/index.php/j/article/view/468

Ms Shelly. (2017). Who Benefit From Essential Drug Price Control, Need of Price Control In India -A review. *Innovative Research Thoughts*, *3*(9), 155–163. Retrieved from https://irt.shodhsagar.com/index.php/j/article/view/247

Ms Shelly. (2017). Current Scenario of Regulatory Affairs In Pharmaceutical Education Sector -A review. *Innovative Research Thoughts*, *3*(9), 145–154. Retrieved from https://irt.shodhsagar.com/index.php/j/article/view/246

Nishchint Makode, Aditya Dabhade, & Onam Dumbare. (2022). LUNG DISEASE DETECTION FROM X-RAYS USING CNN. *International Journal for Research Publication and Seminar*, *13*(3), 103–106. Retrieved from https://jrps.shodhsagar.com/index.php/j/article/view/541

Palmer, A. C., & Sorger, P. K. (2017). Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell, 171(7), 1678–1691.e13.

Patrono, C., & Baigent, C. (2019). Role of aspirin in primary prevention of cardiovascular disease. Nature Reviews Cardiology, 16(11), 675–686.

Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., ... & Leach, A. R. (2019). Drug repurposing: progress, challenges and recommendations. Nature Reviews Drug Discovery, 18(1), 41–58.

Rajkumar, S. V. (2008). Thalidomide therapy and deep vein thrombosis in multiple myeloma. Mayo Clinic Proceedings, 83(8), 917–921.

Ritcha Saxena, Ishrat Nur Ridi, & Kevin Carnewale. (2023). Towards Inclusive Excellence: Advancing Diversity and Equity in Medical Education. *International Journal for Research Publication and Seminar*, *14*(4), 192–203. Retrieved from https://jrps.shodhsagar.com/index.php/j/article/view/441

Sharma, N. (2018). Green Chemistry: A practical elegance in chemical synthesis. *Innovative Research Thoughts*, *4*(2), 47–52. Retrieved from https://irt.shodhsagar.com/index.php/j/article/view/469